Decreased endostatin in db/db retinas is associated with optic disc intravitreal vascularization

Bonet, Aina; Valença, Andreia; Mendes-Jorge, Luísa; Casellas, Alba; Rodríguez‐Baeza, Alfonso; Nacher, Víctor; Ramos, David; Pampalona, Judit; Simó, Rafael; Ruberte, Jesús

doi:10.1016/j.exer.2021.108801

Cited by 4 publications

(3 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bipolar cells can accept inputs from photoreceptors and transmit signals to retinal ganglion cells ( Szabo et al, 2017 ; Eggers and Carreon, 2020 ). Endostatin, an antiangiogenic protein that exists in bipolar cells, is a naturally cleaved fragment of type XVIII collagen ( Bonet et al, 2021 ). This protein is mainly expressed in bipolar cells and photoreceptor cells.…”

Section: Involved Cellsmentioning

confidence: 99%

“…Currently, there are few reports related to bipolar cells in DR. One study has suggested that it is highly vulnerable to high glucose levels ( Wang Y. et al, 2017 ). In diabetic mice, the appearance of intravitreal vessels was shown to be associated with a decrease in endostatin levels in the retina ( Bonet et al, 2021 ). In addition, high sugar levels can induce the production of reactive metabolites such as methylglyoxal (MG), which results in decreased function of bipolar cells because MG is the most reactive glycation precursor of cytotoxic end products ( Schlotterer et al, 2019 ).…”

Section: Involved Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Diabetic retinopathy: Involved cells, biomarkers, and treatments

et al. 2022

View full text Add to dashboard Cite

Diabetic retinopathy (DR), a leading cause of vision loss and blindness worldwide, is caused by retinal neurovascular unit dysfunction, and its cellular pathology involves at least nine kinds of retinal cells, including photoreceptors, horizontal and bipolar cells, amacrine cells, retinal ganglion cells, glial cells (Müller cells, astrocytes, and microglia), endothelial cells, pericytes, and retinal pigment epithelial cells. Its mechanism is complicated and involves loss of cells, inflammatory factor production, neovascularization, and BRB impairment. However, the mechanism has not been completely elucidated. Drug treatment for DR has been gradually advancing recently. Research on potential drug targets relies upon clear information on pathogenesis and effective biomarkers. Therefore, we reviewed the recent literature on the cellular pathology and the diagnostic and prognostic biomarkers of DR in terms of blood, protein, and clinical and preclinical drug therapy (including synthesized molecules and natural molecules). This review may provide a theoretical basis for further DR research.

show abstract

Section: Involved Cellsmentioning

confidence: 99%

Section: Involved Cellsmentioning

confidence: 99%

Diabetic retinopathy: Involved cells, biomarkers, and treatments

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Endostatin is a 20 kDa protein fragment derived from the C-terminus of type XVIII collagen [152,153] . It functions as an angiogenesis inhibitor, suppressing the invasion, migration, and proliferation of endothelial cells [154,155] .…”

Section: Endostatinmentioning

confidence: 99%

Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future Prospects

Zhang,

Lu,

et al. 2023

Preprint

View full text Add to dashboard Cite

Abnormal ocular angiogenesis is a key factor in the development of many blinding ocular diseases, including wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), pathologic myopia with choroidal neovascularization (PM-CNV), and neovascular glaucoma (NVG). The development of anti-neovascular drugs and ocular drug delivery systems (DDS) offers more possibilities for the treatment of neovascular eye diseases. In addition to anti-vascular endothelial growth factor (anti-VEGF) agents, the discovery of other anti-angiogenic targets, such as somatostatin, endostatin and pigment epithelium-derived factor (PEDF), has been a boon to patients with poor anti-VEGF efficacy and led to a reduction in the adverse effects of long-term VEGF inhibition. Gene therapy is currently a very promising approach for the treatment of neovascular ophthalmopathy. The rapid development of gene therapy and the potential for viral vector-mediated gene delivery to achieve sustained expression of anti-vascular substances at the lesion site will mitigate the risks associated with frequent intraocular injections for patients. This review provides an overview of several neovascular ophthalmopathies, discusses the use of anti-vascular therapeutic agents and common DDS, and summarizes treatment strategies and future perspectives for neovascular ophthalmopathy.

show abstract